Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

17 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Fusobacterium is toxic for head and neck squamous cell carcinoma and its presence may determine a better prognosis.
Chander A, Iacovacci J, Pellon A, Kataria R, Grigoriadis A, Maher J, Sears C, Bachrach G, Urbano TG, Lei M, Petkar I, Kong A, Ng T, Orlandi E, Iacovelli NA, De Cecco L, Serafini MS, Moyes D, Rancati T, Ferreira MR. Chander A, et al. Among authors: petkar i. Cancer Commun (Lond). 2024 Aug;44(8):879-883. doi: 10.1002/cac2.12588. Epub 2024 Jul 6. Cancer Commun (Lond). 2024. PMID: 38970403 Free PMC article. No abstract available.
Safety and Treatment Outcomes of Nivolumab for the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Retrospective Multicenter Cohort Study.
Vasiliadou I, Breik O, Baker H, Leslie I, Sim VR, Hegarty G, Michaelidou A, Nathan K, Hartley A, Good J, Sanghera P, Fong C, Urbano TG, Lei M, Petkar I, Ferreira MR, Nutting C, Wong KH, Newbold K, Harrington K, Bhide S, Kong A. Vasiliadou I, et al. Among authors: petkar i. Cancers (Basel). 2021 Mar 19;13(6):1413. doi: 10.3390/cancers13061413. Cancers (Basel). 2021. PMID: 33808781 Free PMC article.
TNM 8 staging is a better prognosticator than TNM 7 for patients with locally advanced oral cavity squamous cell carcinoma treated with surgery and post-operative radiotherapy.
Sambasivan K, Sassoon I, Thavaraj S, Kennedy R, Doss G, Michaelidou A, Odell E, Sandison A, Hall G, Morgan P, Collins LHC, Lyons A, Cascarini L, Fry A, Oakley R, Simo R, Jeannon JP, Petkar I, Reis Ferreira M, Kong A, Lei M, Guerrero Urbano T. Sambasivan K, et al. Among authors: petkar i. Radiother Oncol. 2021 Jul;160:54-60. doi: 10.1016/j.radonc.2021.04.003. Epub 2021 May 3. Radiother Oncol. 2021. PMID: 33845044
Clinical outcomes in relapsed oropharyngeal cancer after definitive (chemo) radiotherapy.
De Felice F, Bird T, Michaelidou A, Jeannon JP, Simo R, Oakley R, Lyons A, Fry A, Cascarini L, Asit A, Thavaraj S, Reis Ferreira M, Petkar I, Kong A, Lei M, Guerrero Urbano T. De Felice F, et al. Among authors: petkar i. Oral Dis. 2023 Mar;29(2):595-603. doi: 10.1111/odi.13985. Epub 2021 Aug 27. Oral Dis. 2023. PMID: 34338394
Protocol letter: Intra-treatment Image Guided Adaptive Radiotherapy Dose-escalation Study (InGReS) - A Phase 1 multicentre feasibility study.
Adjogatse D, Michaelidou A, Sanchez Nieto B, Kozarski R, Sassoon I, Evans M, Rackley T, Shah S, Eaton D, Pike L, Curry S, Gould SM, Thomas C, Kong A, Petkar I, Reis-Ferreira M, Connor S, Barrington SF, Lei M, Guerrero Urbano T. Adjogatse D, et al. Among authors: petkar i. Radiother Oncol. 2023 Jun;183:109645. doi: 10.1016/j.radonc.2023.109645. Epub 2023 Mar 28. Radiother Oncol. 2023. PMID: 36997123 No abstract available.
Dysphagia-optimised intensity-modulated radiotherapy versus standard intensity-modulated radiotherapy in patients with head and neck cancer (DARS): a phase 3, multicentre, randomised, controlled trial.
Nutting C, Finneran L, Roe J, Sydenham MA, Beasley M, Bhide S, Boon C, Cook A, De Winton E, Emson M, Foran B, Frogley R, Petkar I, Pettit L, Rooney K, Roques T, Srinivasan D, Tyler J, Hall E; DARS Trialist Group. Nutting C, et al. Among authors: petkar i. Lancet Oncol. 2023 Aug;24(8):868-880. doi: 10.1016/S1470-2045(23)00265-6. Epub 2023 Jul 6. Lancet Oncol. 2023. PMID: 37423227 Free article. Clinical Trial.
DARS: a phase III randomised multicentre study of dysphagia- optimised intensity- modulated radiotherapy (Do-IMRT) versus standard intensity- modulated radiotherapy (S-IMRT) in head and neck cancer.
Petkar I, Rooney K, Roe JW, Patterson JM, Bernstein D, Tyler JM, Emson MA, Morden JP, Mertens K, Miles E, Beasley M, Roques T, Bhide SA, Newbold KL, Harrington KJ, Hall E, Nutting CM. Petkar I, et al. BMC Cancer. 2016 Oct 6;16(1):770. doi: 10.1186/s12885-016-2813-0. BMC Cancer. 2016. PMID: 27716125 Free PMC article.
17 results